Under the normalization of centralized procurement, the enthusiasm of pharmaceutical companies to participate will be further enhanced!

The seventh batch of national mining bids that have attracted much attention is coming soon! Some people in the industry estimate based on the past rhythm.
After the number of reports, the official centralized procurement document is expected to be released around the beginning of March, and the official quotation and bid opening will be made in April and May, and may be implemented in the third quarter
.
This centralized procurement involves 58 varieties and 208 specifications, involving cardiovascular, diabetes, tumor, antibiotics, neuropsychiatry and other therapeutic fields
.
Judging from the results of the first six batches of centralized procurement, a total of 234 kinds of drugs were purchased, and the amount involved accounted for 30% of the total annual drug purchases by public medical institutions
.
According to relevant statistics, the seventh batch of centralized procurement has a greater impact on the procurement market, and the market size involved has reached about 35 billion yuan
.
So, what about the enthusiasm of pharmaceutical companies to participate in the seventh batch of national procurement? According to the notice document on the seventh batch of national procurement-related work issued by Shanghai Sunshine Pharmaceutical Purchasing Network on February 17, about 220 pharmaceutical companies have entered the bureau in this round of centralized procurement, including domestic pharmaceutical companies including Qilu Pharmaceuticals and Kelun Pharmaceuticals.
, Yangtze River Pharmaceutical, Chia Tai Tianqing, etc.
; multinational pharmaceutical companies such as Pfizer, Roche, Novartis,
etc.
From the perspective of pharmaceutical companies with a large number of shortlisted varieties, local pharmaceutical companies Qilu Pharmaceutical and Kelun Pharmaceutical have more than 10 shortlisted varieties
.
In the previous competition of national procurement, Qilu Pharmaceutical's performance has been very outstanding.
Among the first five batches of national procurement Qilu Pharmaceutical, a total of 11 varieties won the bid
.
The varieties included in the report of Qilu Pharmaceutical include afatinib maleate tablets, aripiprazole orally disintegrating tablets, tenofovir fumarate alafenamide tablets, lenvatinib mesylate capsules, cefixime Capsules, Cefminox Sodium for Injection, Ibandronate Sodium Injection, Edaravone Injection, Zoledronic Acid Injection, Ondansetron Hydrochloride Injection, Metformin Vildagliptin Tablets, Leflunomide Tablets, cefepime hydrochloride for injection
.
Among them, the four varieties of Ondansetron Hydrochloride Injection, Metformin Vildagliptin Tablets, Leflunomide Tablets, and Cefepime Hydrochloride for Injection are the first domestic companies to review
.
Among multinational pharmaceutical companies, Pfizer, Roche and Novartis have 5, 4 and 4 shortlisted varieties respectively
.
In the fifth batch of national procurement, a total of 11 products from 10 multinational pharmaceutical companies were selected.
It can be seen that the enthusiasm of multinational pharmaceutical companies to participate in centralized procurement has been greatly improved
.
In this round of national procurement, the choice of multinational pharmaceutical companies will also continue to attract attention
.
Judging from the attitude of pharmaceutical companies to this centralized procurement, the enthusiasm of pharmaceutical companies to participate in national procurement is further increasing
.
However, the number of over-rated companies for some large varieties has exceeded 10
.
For example, 24 companies have over-rated omeprazole injection, and 13 have over-rated for tenofovir alafenamide oral normal-release dosage form
.
With the launch of the seventh batch of centralized procurement, it is expected that the competition of these varieties of enterprises may be very fierce
.
Not only national procurement, but also local centralized procurement is also normalized
.
For example, on February 25, the Yangtze River Delta Alliance's centralized procurement officially opened the bid.
Although the bid-winning status of the 47 varieties participating in the bidding has not yet been announced, the industry expects that after this alliance's centralized procurement, many varieties will win the bid in the previous national procurement.
On the basis of the price, it has further decreased, but the overall extent is relatively limited
.
Many pharmaceutical companies are embracing centralized procurement with a positive attitude
.
For example, Puli Pharmaceutical stated on the interactive platform on March 7 that the company’s multiple varieties are actively applying for consistency evaluation and will also actively participate in the new centralized procurement; Changchun Hi-Tech also stated on the interactive platform in February, The registration status of Guangdong Centralized Purchasing Alliance has been announced.
In response to the call for centralized purchasing to reduce fees, Jinsai Pharmaceutical has declared three powder specifications, but the liquid has not been declared
.
In the next step, the company will continue to actively participate in the centralized procurement work, pay close attention to and actively respond to the quotations of powder products that have been declared, and at the same time take into account the interests of the company and shareholders in accordance with laws and regulations
.
Some people in the industry believe that in the future, the centralized procurement of alliances may become more and more common, and it will also have an increasing impact on related enterprises
.
In this context, pharmaceutical companies also need to be prepared to face challenges
.